Project Grant R43NS137874
Award Date
7/2/24
Completion Date
3/31/25
Dollars Obligated
$460K
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This Project Grant award, funded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866), is focused on developing a novel therapy to address protein misfolding and aggregation, which are central features of many neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis.
The $349,854 award, with a project period from September 2024 to August 2026, supports the investigation of new molecular...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of amyloid precursor protein (APP) as novel therapies for Alzheimer's disease (AD). The goal is to identify lead compounds that can effectively degrade APP, thereby reducing amyloid-beta (Aβ) production and accumulation, which plays a key role in AD pathogenesis. The project will involve...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $310,000 to the Regents of the University of Minnesota to assess the therapeutic potential of the anticancer agent silmitasertib in treating memory loss associated with frontotemporal dementia (FTD). The researchers will evaluate the impact of the CK2 inhibitor silmitasertib on learning, memory, and synaptic function in FTD mouse models, with the goal of establishing proof-of-concept for...
The National Institute on Aging (NIA) awarded a $299,989 Project Grant under the Aging Research program (CFDA 93.866) to Panorama Research Inc., a for-profit organization, to develop an immunotherapy targeting mutant poly-GA proteins implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Through this 1.5-year project, the company will humanize lead antibodies and conduct preclinical validation of the anti-GA antibody therapy in multiple disease-relevant mouse models....
The federal Project Grant award R41AG084384, in the amount of $506,451, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to 3P Biotechnologies, Inc. The grant supports the development of a targeted exosomal delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, with a focus on Alzheimer's disease. The key products and services to be delivered under this grant...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $224,140 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research aimed at understanding the relationship between cortical hyperexcitability and the progression of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) pathology and behavioral deficits in mice. The research project, which runs from September 1, 2024 to August...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $460,625 will support a mechanistic investigation of innate immunity in a Drosophila (fruit fly) model of frontotemporal dementia (FTD). The research, to be conducted at the University of Massachusetts Medical School, aims to explore the role of antimicrobial peptides, particularly Metchnikowin (MTK), in mediating the neurotoxic effects of dipeptide repeat proteins associated with...
This $244,590 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by Mayo Clinic Jacksonville (a nonprofit organization) to investigate the role of the TMEM106B protein in the pathogenesis of frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), a form of frontotemporal dementia. The key objectives are to: 1) Identify specific protein interactions of TMEM106B fibrils in postmortem FTLD-TDP and non-diseased brains, to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $433,824 to the J. David Gladstone Institutes in San Francisco, CA to investigate how the Alzheimer's disease risk factor APOE4 disrupts the maturation and integration of adult-born dentate granule cells in the hippocampus. The research aims to elucidate the underlying transcriptomic changes and electrophysiological alterations that lead to hyperexcitability in these neurons, with the...
This $4,893,884 Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research federal grant program (CFDA 93.866). The University of Florida will lead a collaborative effort to understand the role of central and peripheral immune crosstalk in frontotemporal dementia with progranulin mutations (FTD-GRN), an Alzheimer's disease-related dementia.
The University of Florida and sub-awardees the J. David Gladstone...